Emergent BioSolutions Inc.

NYSE:EBS Rapporto sulle azioni

Cap. di mercato: US$513.7m

Emergent BioSolutions Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Joe Papa

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOless than a year
Proprietà del CEOn/a
Durata media del management1.7yrs
Durata media del Consiglio di amministrazione3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth

Nov 09
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Nov 08

Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Oct 04

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 18

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process

Jul 15

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

May 10

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Dec 18

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Nov 23

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Aug 23

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Aug 14

Emergent BioSolutions: Making A Big Bet On Narcan

Jul 21

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

AMMINISTRATORE DELEGATO

Joe Papa (68 yo)

less than a year

Mandato

Mr. Joseph C. Papa, Jr. also known as Joe, is Independent Non-Executive Director of Milestone Pharmaceuticals Inc. since September 3, 2024. Mr. Papa serves as Executive Advisor at Water Street Healthcare P...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Richard Lindahl
Executive VP6.7yrsUS$2.18m0.32%
$ 1.6m
Coleen Glessner
Executive Vice President of Global Quality and Ethics & Compliance2.6yrsUS$1.68m0.30%
$ 1.5m
Paul Williams
Senior Vice President of Products Business1.8yrsUS$1.06m0.045%
$ 230.7k
Joseph Papa
CEO, President & Directorless than a yearNessun datoNessun dato
Jessica Perl
Senior VPless than a yearNessun dato0.013%
$ 64.5k
Michelle Pepin
Senior VP & Chief Human Resource Officer1.7yrsNessun datoNessun dato
Stephanie Duatschek
Senior VP1.7yrsNessun datoNessun dato
William Hartzel
Senior Vice President of Manufacturing & Bioservicesno dataNessun dato0.088%
$ 450.1k
Simon Lowry
Senior VP of Research & Development and Chief Marketing Officerno dataNessun datoNessun dato

1.7yrs

Durata media

58.5yo

Età media

Gestione esperta: Il team dirigenziale di EBS non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Joseph Papa
CEO, President & Directorless than a yearNessun datoNessun dato
Louis Sullivan
Independent Director18.4yrsUS$400.23k0.099%
$ 506.4k
Ronald Richard
Independent Director19.8yrsUS$394.73k0.037%
$ 188.1k
Donald DeGolyer
Independent Director1.1yrsUS$397.50k0.027%
$ 138.0k
Keith Katkin
Independent Director2.6yrsUS$396.99k0.011%
$ 54.3k
Marvin White
Independent Director4.1yrsUS$405.98k0.068%
$ 347.5k
Zsolt Harsanyi
Independent Non-Executive Chairman20.3yrsUS$535.98k0.070%
$ 360.7k
Kathryn Zoon
Independent Director8.1yrsUS$413.48k0.068%
$ 351.2k
Neal Fowler
Independent Director1.1yrsUS$398.75kNessun dato
Sujata Dayal
Independent Director2.3yrsUS$382.23k0.0073%
$ 37.4k

3.3yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EBS sono considerati esperti (durata media dell'incarico 3.3 anni).